Companies sponsors |
Alexion (ravulizumab) |
Others |
Department of Health and Social Care |
|
NHS England |
|
Welsh Government |
Patient carer groups |
Muscular Dystrophy UK |
|
myaware |
Professional groups |
Association of British Neurologists |
|
Royal College of Physicians |
|
UK Clinical Pharmacy Association |
Associated public health groups |
None |
Comparator companies |
Bio Products Laboratory (plasma exchange) (confidentiality agreement not signed, not participating) |
|
Biotest UK (plasma exchange) (confidentiality agreement not signed, not participating) |
|
CSL Behring UK (human immunoglobulin plasma exchange) (confidentiality agreement not signed, not participating) |
|
Grifols UK (immunoglobulin, plasma exchange) (confidentiality agreement not signed, not participating) |
|
Napp Pharmaceutical (rituximab) (confidentiality agreement not signed, not participating) |
|
Octapharma (plasma exchange) (confidentiality agreement not signed, not participating) |
|
Pfizer (rituximab) (confidentiality agreement not signed, not participating) |
|
Roche (rituximab) (confidentiality agreement not signed, not participating) |
|
Sandoz (rituximab) (confidentiality agreement not signed, not participating) |
|
Teva UK (plasma exchange) (confidentiality agreement not signed, not participating) |
General commentators |
All Wales Therapeutics and Toxicology Centre |
|
British National Formulary |
|
Department of Health, Social Services and Public Safety for Northern Ireland |
|
Healthcare Improvement Scotland |
|
Medicines and Healthcare products Regulatory Agency |
|
Scottish Medicines Consortium |
|
Welsh Health Specialised Services Committee |
Relevant research groups |
None |